Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Study sponsor: Nurix Therapeutics, Inc. · NRIX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2033-05Estimated
Enrollment · participants150Estimated
Source updated2026-11-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.